Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Morinobu, Seki"'
Autor:
Yuki Momota, Shogyoku Bun, Jinichi Hirano, Kei Kamiya, Ryo Ueda, Yu Iwabuchi, Keisuke Takahata, Yasuharu Yamamoto, Toshiki Tezuka, Masahito Kubota, Morinobu Seki, Ryo Shikimoto, Yu Mimura, Taishiro Kishimoto, Hajime Tabuchi, Masahiro Jinzaki, Daisuke Ito, Masaru Mimura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Previous studies have developed and explored magnetic resonance imaging (MRI)-based machine learning models for predicting Alzheimer’s disease (AD). However, limited research has focused on models incorporating diverse patient populations.
Externí odkaz:
https://doaj.org/article/9d1f58f65cab4220bbb024c0bfc69f91
Autor:
Taku Hatano, Renpei Sengoku, Hiroshi Nagayama, Naotake Yanagisawa, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Kenichi Kaida, Ryoko Ihara, Kazutomi Kanemaru, Osamu Kano
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 323-338 (2024)
Abstract Introduction A higher levodopa dose is a risk factor for motor complications in Parkinson’s disease (PD). Istradefylline (IST) is used as adjunctive treatment to levodopa in PD patients with off episodes, but its impact on levodopa dose ti
Externí odkaz:
https://doaj.org/article/297912391b29425383cd3fe2f9e7b7d9
Autor:
Shogyoku Bun, Daisuke Ito, Toshiki Tezuka, Masahito Kubota, Ryo Ueda, Keisuke Takahata, Sho Moriguchi, Shin Kurose, Yuki Momota, Natsumi Suzuki, Ayaka Morimoto, Yuka Hoshino, Morinobu Seki, Yu Mimura, Ryo Shikimoto, Yasuharu Yamamoto, Takayuki Hoshino, Yoshiaki Sato, Hajime Tabuchi, Masaru Mimura
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-12 (2023)
Abstract Background Plasma biomarkers have emerged as promising screening tools for Alzheimer’s disease (AD) because of their potential to detect amyloid β (Aβ) accumulation in the brain. One such candidate is the plasma Aβ42/40 ratio (Aβ42/40)
Externí odkaz:
https://doaj.org/article/35988baa358f41118985061f582a733e
Autor:
Shogyoku Bun, Sho Moriguchi, Toshiki Tezuka, Yoshiaki Sato, Keisuke Takahata, Morinobu Seki, Shinichiro Nakajima, Yasuharu Yamamoto, Yasunori Sano, Natsumi Suzuki, Ayaka Morimoto, Ryo Ueda, Hajime Tabuchi, Daisuke Ito, Masaru Mimura
Publikováno v:
Neuropsychopharmacology Reports, Vol 42, Iss 4, Pp 437-448 (2022)
Abstract Background Alzheimer’s disease (AD) is the most common cause of dementia worldwide. In AD, abnormal tau accumulates within neurons of the brain, facilitated by extracellular β‐amyloid deposition, leading to neurodegeneration, and eventu
Externí odkaz:
https://doaj.org/article/3637b234e639424a95be9af57061d0bb
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of p
Externí odkaz:
https://doaj.org/article/cfce3a23ad2c4557989e22ae9b726e9c
Autor:
Taku Hatano, Osamu Kano, Renpei Sengoku, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Naotake Yanagisawa, Hiroshi Nagayama
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Levodopa remains the most effective symptomatic treatment for Parkinson’s disease (PD) more than 50 years after its clinical introduction. However, the onset of motor complications can limit pharmacological intervention with lev
Externí odkaz:
https://doaj.org/article/05704b3d790741498c68e0d164b8370b
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 17, p2451-2453, 3p
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Programmed cell death 1 inhibitors have revolutionized therapy for cancer by their outstanding effectiveness. However, they may cause adverse effects, among which inflammatory myopathy is one of the most disabling. To elucidate it
Externí odkaz:
https://doaj.org/article/072018962ee84af2a608325fec17350b
Autor:
Taiga Wakabayashi, Hideaki Obara, Morinobu Seki, Masahiro Shinoda, Minoru Kitago, Hiroshi Yagi, Yuta Abe, Kentaro Matsubara, Yohei Yamada, Go Oshima, Koichi Oki, Narihito Nagoshi, Kota Watanabe, Taizo Hibi, Osamu Itano, Ken Hoshino, Norihiro Suzuki, Tatsuo Kuroda, Yuko Kitagawa
Publikováno v:
Annals of Hepatology, Vol 18, Iss 2, Pp 397-401 (2019)
We report the case of a 53-year-old-man who developed human T-cell leukemia virus type-1-associated myelopathy (HAM) after ABO-incompatible liver transplantation for alcoholic liver cirrhosis. The living donor was seropositive for human T-cell leukem
Externí odkaz:
https://doaj.org/article/ba20fee8d2f1498cb553cc0ea6bc2dc0
Autor:
Sho Shimohama, Toshiki Tezuka, Keisuke Takahata, Shogyoku Bun, Hajime Tabuchi, Morinobu Seki, Yuki Momota, Natsumi Suzuki, Ayaka Morimoto, Yu Iwabuchi, Masahito Kubota, Yasuharu Yamamoto, Yasunori Sano, Ryo Shikimoto, Kei Funaki, Yu Mimura, Yoshinori Nishimoto, Ryo Ueda, Masahiro Jinzaki, Jin Nakahara, Masaru Mimura, Daisuke Ito
Publikováno v:
Neurology. 100:e264-e274
Background and ObjectivesPrevious studies have evaluated the diagnostic effect of amyloid PET in selected research cohorts. However, these studies did not assess the clinical impact of the combination of amyloid and tau PETs. Our objective was to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1b0cfe8e37f754d3af9a01560e9447a
https://doi.org/10.1212/wnl.0000000000201389
https://doi.org/10.1212/wnl.0000000000201389